Published in Schizophr Bull on February 21, 2006
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull (2008) 2.01
Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl) (2010) 1.40
A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology (2012) 1.33
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull (2014) 1.19
Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev (2013) 1.07
Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry (2014) 1.03
Friends and symptom dimensions in patients with psychosis: a pooled analysis. PLoS One (2012) 0.93
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci (2007) 0.92
The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry (2013) 0.89
Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat (2011) 0.89
Olfactory processing, sex effects and heterogeneity in schizophrenia. Schizophr Res (2011) 0.88
Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res (2013) 0.86
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull (2008) 0.85
Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy. Psychiatry Res (2013) 0.84
Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy. BMC Psychiatry (2014) 0.83
Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2013) 0.82
First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol (2012) 0.81
Development of the Positive Emotions Program for Schizophrenia: An Intervention to Improve Pleasure and Motivation in Schizophrenia. Front Psychiatry (2016) 0.80
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl) (2009) 0.80
Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Res (2013) 0.79
Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem. Schizophr Res (2008) 0.79
Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. J Dual Diagn (2007) 0.79
Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task. Behav Brain Res (2013) 0.79
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophr Bull (2015) 0.78
Negative symptoms in youths with psychosis spectrum features: complementary scales in relation to neurocognitive performance and function. Schizophr Res (2015) 0.78
The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia. Schizophr Res (2014) 0.76
Olfactory performance segregates effects of anhedonia and anxiety on social function in patients with schizophrenia. J Psychiatry Neurosci (2015) 0.76
Perception of the duration of emotional faces in schizophrenic patients. Sci Rep (2016) 0.75
Drug discovery in psychiatric illness: mining for gold. Schizophr Bull (2009) 0.75
A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry (1987) 6.83
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry (1997) 5.03
Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry (1982) 4.52
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res (1999) 4.13
The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res (1989) 2.81
Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat Genet (1996) 2.18
Characterization of psychotic conditions. Use of the domains of psychopathology model. Arch Gen Psychiatry (1998) 1.68
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry (1998) 1.51
Odor identification, eye tracking and deficit syndrome schizophrenia. Biol Psychiatry (2002) 1.15
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry (1996) 1.09
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res (1992) 1.09
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res (2004) 1.07
The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking. Mol Psychiatry (1996) 1.06
Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Am J Psychiatry (1997) 1.06
Factor structure of the negative symptom assessment. Psychiatry Res (1994) 1.05
Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models. Am J Psychiatry (1995) 1.05
Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry (1997) 1.05
Oxytocin and vasopressin as candidate genes for psychiatric disorders: lessons from animal models. Am J Med Genet (2001) 1.05
Association between serotonin transporter gene polymorphism and anxiety-related traits. Biol Psychiatry (1999) 1.04
A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry (1999) 1.00
Components of the smooth pursuit function in deficit and nondeficit schizophrenia. Schizophr Res (2003) 0.99
Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol (2003) 0.94
Bipolar II with and without cyclothymic temperament: "dark" and "sunny" expressions of soft bipolarity. J Affect Disord (2003) 0.94
Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs (2003) 0.89
Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol (2002) 0.86
New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl (1995) 0.81
Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am (2003) 0.81
Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull (2002) 0.80
Donepezil in schizophrenia--is it helpful? An experimental design case study. Acta Psychiatr Scand (2001) 0.80
Positive and negative symptoms and and adjustment in severely mentally ill outpatients. Psychiatry Res (1999) 0.79
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2003) 2.83
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
The brief negative symptom scale: psychometric properties. Schizophr Bull (2010) 2.27
Bipolar I disorder: psychopathology, medical management and dental implications. J Am Dent Assoc (2002) 2.15
Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc (2003) 2.09
Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry (2011) 2.02
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv (2007) 1.93
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry (2011) 1.86
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry (2002) 1.68
Maintaining informed consent validity during lengthy research protocols. IRB (2008) 1.62
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2005) 1.58
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull (2009) 1.52
Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology (2009) 1.47
Panic disorder: psychopathology, medical management and dental implications. J Am Dent Assoc (2004) 1.44
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol (2005) 1.39
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull (2010) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull (2009) 1.27
At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull (2012) 1.24
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry (2003) 1.22
Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol (2008) 1.21
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry (2009) 1.20
Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res (2011) 1.20
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res (2013) 1.16
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull (2010) 1.13
Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. Am J Psychiatry (2004) 1.13
Another view of therapy for cognition in schizophrenia. Biol Psychiatry (2002) 1.11
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv (2008) 1.10
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry (2004) 1.09
Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res (2013) 1.09
The psychopathology, medical management and dental implications of schizophrenia. J Am Dent Assoc (2002) 1.08
Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology (2008) 1.07
The heterogeneity of schizophrenia in disease states. Schizophr Res (2004) 1.04
The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophr Bull (2010) 1.02
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
DSM-5 status of psychotic disorders: 1 year prepublication. Schizophr Bull (2012) 1.01
Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia. Biol Psychiatry (2003) 1.01
Optimistic bias in the perception of personal risk: patterns in schizophrenia. Am J Psychiatry (2005) 1.00
A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry (2007) 0.98
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res (2007) 0.98
The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry (2005) 0.98
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry (2004) 0.98
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull (2011) 0.97
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry (2003) 0.96
First- and second-generation antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry (2007) 0.94
Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry (2002) 0.94
The genomic psychiatry cohort: partners in discovery. Am J Med Genet B Neuropsychiatr Genet (2013) 0.94
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull (2009) 0.94
Sexual side effects of novel antipsychotic medications. Schizophr Res (2002) 0.92
A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res (2012) 0.92
Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res (2013) 0.92
Chronic restlessness with antipsychotics. Am J Psychiatry (2007) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry (2004) 0.91
First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs (2005) 0.91
Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophr Res (2011) 0.91
Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol (2011) 0.90
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry (2002) 0.90
Anterior cingulate dysfunction during choice anticipation in schizophrenia. Psychiatry Res (2004) 0.90
Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. Schizophr Res (2005) 0.89
New paradigms for treatment development. Schizophr Bull (2007) 0.89
The costs of drugs for schizophrenia. Am J Psychiatry (2006) 0.88
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry (2008) 0.88
Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties. Schizophr Bull (2013) 0.87
Conceptualizing schizophrenia through attenuated symptoms in the population. Am J Psychiatry (2010) 0.86
Schizophrenia--time to commit to policy change. Schizophr Bull (2014) 0.86
Revisiting the diagnosis of schizophrenia: where have we been and where are we going? CNS Neurosci Ther (2010) 0.86
Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) (2001) 0.86
Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res (2012) 0.86
Switch or stay? Am J Psychiatry (2006) 0.85
Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr Res (2013) 0.84
Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J (2010) 0.84
Posttraumatic stress disorder: psychopathology, medical management, and dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 0.84
In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry (2002) 0.84
Neuroplasticity and schizophrenia. Biol Psychiatry (2004) 0.83
Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit (2003) 0.83